These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34352992)

  • 1. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).
    Rhee SY
    Diabetes Metab J; 2021 Jul; 45(4):619-620. PubMed ID: 34352992
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).
    Schernthaner G
    Diabetes Metab J; 2021 Jul; 45(4):615-616. PubMed ID: 34352990
    [No Abstract]   [Full Text] [Related]  

  • 3. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.
    Scheen AJ
    Diabetes Metab; 2021 Mar; 47(2):101213. PubMed ID: 33249199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.
    Rhee SY; Lee J; Nam H; Kyoung DS; Shin DW; Kim DJ
    Diabetes Metab J; 2021 Mar; 45(2):251-259. PubMed ID: 33752274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer.
    Almagthali AG; Alkhaldi EH; Alzahrani AS; Alghamdi AK; Alghamdi WY; Kabel AM
    Diabetes Metab Syndr; 2019; 13(1):36-39. PubMed ID: 30641726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 and diabetes: Can DPP4 inhibition play a role?
    Iacobellis G
    Diabetes Res Clin Pract; 2020 Apr; 162():108125. PubMed ID: 32224164
    [No Abstract]   [Full Text] [Related]  

  • 8. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
    Said S; Nwosu AC; Mukherjee D; Hernandez GT
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
    Pitocco D; Tartaglione L; Viti L; Di Leo M; Pontecorvi A; Caputo S
    Diabetes Res Clin Pract; 2020 May; 163():108162. PubMed ID: 32335097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
    Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review.
    Berlie HD; Kale-Pradhan PB; Orzechowski T; Jaber LA
    Ann Pharmacother; 2021 Nov; 55(11):1386-1396. PubMed ID: 33657863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.
    Bielka W; Przezak A; Pawlik A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.
    Zhao Y; Yang L; Zhou Z
    J Diabetes; 2014 Jan; 6(1):21-9. PubMed ID: 23683065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INSIGHTS (INSITES) on DPP 4 Inhibitors (Gliptins) for Diabetes Management in India.
    Tiwaskar M
    J Assoc Physicians India; 2019 Oct; 67(10):11-12. PubMed ID: 31571444
    [No Abstract]   [Full Text] [Related]  

  • 16. Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review.
    Turdu G; Gao H; Jiang Y; Kabas M
    Future Med Chem; 2018 May; 10(10):1229-1239. PubMed ID: 29749760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.
    Rakhmat II; Kusmala YY; Handayani DR; Juliastuti H; Nawangsih EN; Wibowo A; Lim MA; Pranata R
    Diabetes Metab Syndr; 2021; 15(3):777-782. PubMed ID: 33838614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who would really benefit from DPP-4 inhibitors?
    Mikhail N
    Endocrine; 2014 May; 46(1):6-7. PubMed ID: 24510631
    [No Abstract]   [Full Text] [Related]  

  • 19. Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes.
    Sehra D; Sehra S
    J Assoc Physicians India; 2011 Nov; 59():744; author reply 744. PubMed ID: 22616349
    [No Abstract]   [Full Text] [Related]  

  • 20. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study.
    Fadini GP; Morieri ML; Longato E; Bonora BM; Pinelli S; Selmin E; Voltan G; Falaguasta D; Tresso S; Costantini G; Sparacino G; Di Camillo B; Tramontan L; Cattelan AM; Vianello A; Fioretto P; Vettor R; Avogaro A
    Diabetes Obes Metab; 2020 Oct; 22(10):1946-1950. PubMed ID: 32463179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.